Back to Stories
PxWire Volume 14, Issue No. 3
Check out the latest issue of PxWire here! And see key highlights below:
- Since the enactment of Uganda’s Anti-Homosexuality Act in March 2023, the number of new PrEP initiations plummeted.
- An analysis presented at AIDS 2024, found that 69% of 194 countries reviewed have approved at least one PrEP product. However, only 52% of these countries adhere to WHO guidance on PrEP eligibility.
- Three generic manufacturers have licenses to develop generic versions of injectable cabotegravir (CAB) for PrEP.
- Results from the PURPOSE 1 trial of injectable lenacapavir showing 100% efficacy in preventing HIV among cisgender women and adolescent girls dominated headlines at the AIDS 2024 conference.